ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 2020

Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1868

B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease

Muscle Biology, Myositis and Myopathies Poster II

1:00PM-3:00PM: Abstract Number: 1713

Bank1 Signaling Shapes the Gut Microbiota Composition by Controlling the Gut Mucosal B-cell Response in Lupus

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 1995

Baricitinib Improves Bone Biomechanical Properties in Rheumatoid Arthritis (RA) – Results of a Prospective Interventional Study

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 2133

Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 1911

Baseline Bone Curvature a Biomarker for the Prediction of Knee Osteoarthritis Cartilage Volume Loss at One-Year. Use of Machine Learning

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 1727

BATF Represses BIM Expression to Sustain the T Cell Anergy Program

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 1906

Bile Acid Profile Is Associated to Synovitis in Knee Osteoarthritis

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 2117

Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: L14

Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

(L07–L17) Late-Breaking Abstract Poster

1:00PM-3:00PM: Abstract Number: 2122

Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 2119

Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 1844

Biological Therapy in Neurosarcoidosis: Study of 30 Patients from a Series of 234 Systemic Sarcoidosis from a University Hospital

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 1688

Biomechanical Phenotype of Circulating Neutrophils Is Altered in ANCA Associated Vasculitis

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 2178

BNT162b2 mRNA Vaccine Against Covid 19, Humoral Response, Safety and Efficacy in Scleroderma Patients

Systemic Sclerosis and Related Disorders – Clinical Poster III

«Previous Page
1
…
7
8
9
10
11
…
45
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].